KAT7

Summary

KAT7 (lysine acetyltransferase 7, HGNC:17016) is a protein-coding gene on chromosome 17q21.33, encoding Histone acetyltransferase KAT7 (O95251). Catalytic subunit of histone acetyltransferase HBO1 complexes, which specifically mediate acetylation of histone H3 at ‘Lys-14’ (H3K14ac), thereby regulating various processes, such as gene transcription, protein ubiquitination, immune regulation, stem cell pluripotent and self-…. It is a selective cancer dependency (DepMap: 15.3% of cell lines).

The protein encoded by this gene is part of the multimeric HBO1 complex, which possesses histone H4-specific acetyltransferase activity. This activity is required for functional replication origins and is involved in transcriptional activation of some genes. In both cases, the acetylation of histone H4 helps unfold chromatin so that the DNA can be accessed and replicated or transcribed.

Source: NCBI Gene 11143 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 66 total
• Druggable target: yes
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• Cancer dependency (DepMap): dependent in 15.3% of screened cell lines
• Transcription factor: yes — 87 downstream targets (CollecTRI)
• MANE Select transcript: NM_007067

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17016
Approved symbol	KAT7
Name	lysine acetyltransferase 7
Location	17q21.33
Locus type	gene with protein product
Status	Approved
Aliases	HBOA, HBO1
Ensembl gene	ENSG00000136504
Ensembl biotype	protein_coding
OMIM	609880
Entrez	11143

Gene structure

Transcript identifiers

Ensembl transcripts: 37 — 20 protein_coding, 10 retained_intron, 5 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000259021, ENST00000424009, ENST00000435742, ENST00000454930, ENST00000503101, ENST00000503635, ENST00000506533, ENST00000508594, ENST00000509124, ENST00000509773, ENST00000509794, ENST00000510426, ENST00000510819, ENST00000512616, ENST00000513075, ENST00000513171, ENST00000513980, ENST00000514540, ENST00000675278, ENST00000706506, ENST00000706507, ENST00000706508, ENST00000706509, ENST00000706510, ENST00000706511, ENST00000706512, ENST00000706513, ENST00000706629, ENST00000706630, ENST00000706637, ENST00000706638, ENST00000706639, ENST00000706640, ENST00000706641, ENST00000706642, ENST00000706643, ENST00000710381

RefSeq mRNA: 6 — MANE Select: NM_007067 NM_001199155, NM_001199156, NM_001199157, NM_001199158, NM_001346706, NM_007067

CCDS: CCDS11554, CCDS56035, CCDS56036, CCDS56037, CCDS56038

Canonical transcript exons

ENST00000259021 — 15 exons

Exon	Start	End
ENSE00001109544	49805363	49805445
ENSE00001137594	49811476	49811574
ENSE00002018965	49788681	49788849
ENSE00002293812	49827401	49835026
ENSE00003458411	49826693	49826799
ENSE00003459825	49826000	49826146
ENSE00003537748	49796750	49796926
ENSE00003631380	49821337	49821426
ENSE00003653115	49815803	49815913
ENSE00003657080	49823202	49823295
ENSE00003679127	49817820	49818011
ENSE00003693317	49821650	49821790
ENSE00003694358	49791886	49792033
ENSE00003995998	49798319	49798558
ENSE00003996008	49809119	49809208

Expression profiles

Bgee: expression breadth ubiquitous, 286 present calls, max score 95.20.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 60.9415 / max 678.3607, expressed in 1825 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161549	59.8412	1825
161552	1.1003	238

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	95.20	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.36	gold quality
testis	UBERON:0000473	92.81	gold quality
left testis	UBERON:0004533	92.73	gold quality
calcaneal tendon	UBERON:0003701	92.66	gold quality
right testis	UBERON:0004534	92.64	gold quality
ventricular zone	UBERON:0003053	92.32	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	92.14	gold quality
colonic epithelium	UBERON:0000397	92.13	gold quality
popliteal artery	UBERON:0002250	91.70	gold quality
tibial artery	UBERON:0007610	91.68	gold quality
ganglionic eminence	UBERON:0004023	91.59	gold quality
muscle of leg	UBERON:0001383	91.18	gold quality
cerebellar cortex	UBERON:0002129	91.15	gold quality
cerebellar hemisphere	UBERON:0002245	91.15	gold quality
gastrocnemius	UBERON:0001388	91.09	gold quality
adult organism	UBERON:0007023	91.00	gold quality
tibialis anterior	UBERON:0001385	90.91	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.81	gold quality
aorta	UBERON:0000947	90.52	gold quality
cerebellum	UBERON:0002037	90.48	gold quality
descending thoracic aorta	UBERON:0002345	90.19	gold quality
sperm	CL:0000019	90.18	gold quality
hindlimb stylopod muscle	UBERON:0004252	90.14	gold quality
bone marrow cell	CL:0002092	90.13	gold quality
prefrontal cortex	UBERON:0000451	90.12	gold quality
body of uterus	UBERON:0009853	89.95	gold quality
male germ cell	CL:0000015	89.93	gold quality
secondary oocyte	CL:0000655	89.77	gold quality
islet of Langerhans	UBERON:0000006	89.67	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-130473	yes	9095.06
E-ANND-3	yes	7.91
E-MTAB-7008	no	448.39

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

87 targets.

Target	Regulation
AGT
ALAS2
APC
APP
BCLAF1
BGLAP
BIRC3
BTK
CARM1
CCNA2
CCND1
CCNE1
CD4
CD74
CDKN1A
CDKN1B
CFTR
COL1A2
COMT
CREBBP
CSF2
CXCL8
CYP24A1
DIO1
DRD2
EP400
FGFR1
FTH1
GCM1
GRIP1

Upstream regulators (CollecTRI, top): CEBPA

miRNA regulators (miRDB)

117 targeting KAT7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4697-3P	99.89	67.09	1123
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-3151-5P	99.86	63.83	1069

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 15.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• inhibition by Set/TAF-1beta inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing (PMID:11978794)
• ordered recruitmenet to thyroid hormone-responsive promoters in vivo (PMID:12034878)
• Hbo1 is a positive regulatory factor for prereplicative complex assembly. (PMID:16428461)
• histone acetyltransferase binding to ORC-1 might play an important physiological role in human progesterone receptor signaling (PMID:16645042)
• reveal a direct regulatory connection between p53-responsive stress signaling and Hbo1-dependent chromatin pathways (PMID:17954561)
• Hbo1 depletion results in decreased DNA replication and a failure of Mcm complex binding to chromatin, both of which can be partially rescued by the ectopic expression of WT Hbo1 but not Hbo1-S57A (PMID:18250300)
• Jade-1/1L are crucial co-factors for HBO1-mediated histone H4 acetylation (PMID:18684714)
• HBO1 associates with replication origins specifically during the G1 phase of the cell cycle in a manner that depends on the replication licensing factor Cdt1, but is independent of the Cdt1 repressor Geminin. (PMID:18832067)
• Overexpression of MYST2 is associated with breast cancer. (PMID:19372580)
• Immunohistochemistry for Hbo1 in 11 primary human tumor types revealed strong Hbo1 protein expression in carcinomas of the testis, ovary, breast, stomach/esophagus, and bladder. (PMID:19393168)
• results show that ING4 is a bivalent reader of the chromatin H3K4me3 modification and suggest a mechanism for enhanced targeting of the HBO1 complex to specific chromatin sites (PMID:20053357)
• H4 acetylation at origins by HBO1 is critical for DNA replication licensing. (PMID:20129055)
• HBO1 promote MCM loading in vivo involves the stimulation of large-scale chromatin decondensation to allow access to the underlying DNA substrate. (PMID:20980834)
• HBO1 was an important downstream molecule of ERalpha. (PMID:21040551)
• JNK1 phosphorylation of Cdt1 inhibits recruitment of HBO1 histone acetylase and blocks replication licensing in response to stress (PMID:21856198)
• The protein domains required for the assembly and function of HBO1/ING complexes were shown. Multiple PHD finger domains in different subunits bound the histone H3 N-terminal tail with a specificity towards lysine 4 methylation. (PMID:22144582)
• Gemcitabine resistance is dependent on Plk1-mediated phosphorylation of Orc2 and Hbo1. (PMID:23188630)
• Modulation of Fbxw15 levels was able to differentially regulate histone H3K14 acetylation and cellular proliferation by altering HBO1 levels. (PMID:23319590)
• HBO1, but not SRC-2, expression was reduced in testes of patients with androgen insensitivity syndromes compared to normal testes. (PMID:23707616)
• Phosphorylated Hbo1 expression is associated with breast cancer. (PMID:23955388)
• alternate choice of subunits associated with HBO1 can switch its specificity between H4 and H3 tails (PMID:24065767)
• Hbo1 modulated transcription by estrogen receptor-alpha. Hbo1 contributes to degradation of ER-alpha by ubiquitination through lysine 48. (PMID:24125069)
• Increase in the number of cells with cytoplasmic JADE1S correlated with activation of tubular cell proliferation and inversely correlated with the number of cells with nuclear JADE1S, supporting role of HBO1-JADE1 shuttling during organ regeneration. (PMID:24739512)
• Myst2-mediated histone acetylation may be required for recruitment of Oct4 to the Nanog promoter (PMID:25743411)
• Taken together, MYST2 is a repressed growth suppressor in AML mediating reduced acetylation of histone 4 at residue 5 and is associated with inferior AML patient survival. (PMID:26072331)
• This study demonstrates that CRL4(DDB2) is a novel ubiquitin ligase of HBO1. (PMID:26572825)
• Data show that HTLV-1 basic leucine zipper (bZIP) factor (HBZ) represses p53 activity by direct inhibition of the histone acetyltransferase (HAT) activity of p300/CBP and the HAT activity of HBO1: [HBZ] (PMID:26625199)
• the possible binding sites and biological functions of HBO1, were identified. (PMID:27247147)
• KAT7-containing acetyltransferases associating with the Mis18 complex provides competence for histone turnover/exchange activity on alphoid DNA and prevents Suv39h1-mediated heterochromatin invasion into centromeres. (PMID:27270040)
• Structural and mechanistic insights into regulation of HBO1 histone acetyltransferase activity by BRPF2 have been presented. (PMID:28334966)
• The results demonstrate some connections between KAT7 upregulated in RA SFs and RA progression and present the inhibition of KAT7 activity as a novel therapeutic target for interfering RA disease. (PMID:28552525)
• acts in concert with SNF2H-ACF1 to make the chromosome structure more accessible to canonical nucleotide excision repair factors (PMID:28719581)
• Hbo1 is another ERalpha coactivator that ubiquitinates ERalpha (PMID:28769019)
• Histone acetyltransferase binding to ORC1 (HBO1) is upregulated in bladder cancer. (PMID:28796367)
• results indicate that the N-terminal region of JADE1 functions as a platform that brings together the catalytic HBO1 subunit with its cognate H3-H4 substrate for histone acetylation (PMID:29382722)
• These findings indicate that USP25 promotes stability of HBO1 in bacterial infection thereby enhances HBO1-mediated inflammatory gene transcription. (PMID:30745998)
• HBO1 preferentially acetylates histone H4 through the concomitant overexpression of co-regulator JADE2, and is required for the expression of YAP1, an ovarian cancer oncogene and mechano-transductor signaling factor. (PMID:30759370)
• These data suggest that LYAR promotes the association of the BRD2-KAT7 and BRD4-KAT7 complexes with transcription-competent rDNA loci but not to transcriptionally silent rDNA loci, thereby increasing rRNA synthesis by altering the local acetylation status of histone H3 and H4. (PMID:31504794)
• As the core catalytic subunit, HBO1 consists of an N-terminal domain and a C-terminal MYST domain that are in charge of acetyl-CoA binding and acetylation reaction. This paper reviews the recent advances and discusses the understanding of the multiple functions, activity regulation, and disease relationship of HBO1. [review] (PMID:31535175)
• UHRF1-KAT7-mediated regulation of TUSC3 expression via histone methylation/acetylation is critical for the proliferation of colon cancer cells. (PMID:31582837)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	kat7b	ENSDARG00000031770
mus_musculus	Kat7	ENSMUSG00000038909
rattus_norvegicus	Kat7	ENSRNOG00000022664
caenorhabditis_elegans		WBGENE00045419

Paralogs (9): DPF1 (ENSG00000011332), RSF1 (ENSG00000048649), KAT6A (ENSG00000083168), KAT8 (ENSG00000103510), PHF10 (ENSG00000130024), DPF2 (ENSG00000133884), KAT6B (ENSG00000156650), KAT5 (ENSG00000172977), DPF3 (ENSG00000205683)

Protein

Protein identifiers

Histone acetyltransferase KAT7 — O95251 (reviewed: O95251)

Alternative names: Histone acetyltransferase binding to ORC1, Lysine acetyltransferase 7, MOZ, YBF2/SAS3, SAS2 and TIP60 protein 2

All UniProt accessions (17): A0A6Q8PHH2, A0A9L9PWZ9, A0A9L9PX04, A0A9L9PX81, A0A9L9PXC5, A0A9L9PXJ9, A0A9L9PXL5, A0A9L9PXM0, A0A9L9PXP8, A0A9L9PXR4, A0A9L9PXR9, A0A9L9PY29, A0AA34QVH8, B4DGH8, D6RFZ5, E7EUP3, O95251

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic subunit of histone acetyltransferase HBO1 complexes, which specifically mediate acetylation of histone H3 at ‘Lys-14’ (H3K14ac), thereby regulating various processes, such as gene transcription, protein ubiquitination, immune regulation, stem cell pluripotent and self-renewal maintenance and embryonic development. Some complexes also catalyze acetylation of histone H4 at ‘Lys-5’, ‘Lys-8’ and ‘Lys-12’ (H4K5ac, H4K8ac and H4K12ac, respectively), regulating DNA replication initiation, regulating DNA replication initiation. Specificity of the HBO1 complexes is determined by the scaffold subunit: complexes containing BRPF scaffold (BRPF1, BRD1/BRPF2 or BRPF3) direct KAT7/HBO1 specificity towards H3K14ac, while complexes containing JADE (JADE1, JADE2 and JADE3) scaffold direct KAT7/HBO1 specificity towards histone H4. H3K14ac promotes transcriptional elongation by facilitating the processivity of RNA polymerase II. Acts as a key regulator of hematopoiesis by forming a complex with BRD1/BRPF2, directing KAT7/HBO1 specificity towards H3K14ac and promoting erythroid differentiation. H3K14ac is also required for T-cell development. KAT7/HBO1-mediated acetylation facilitates two consecutive steps, licensing and activation, in DNA replication initiation: H3K14ac facilitates the activation of replication origins, and histone H4 acetylation (H4K5ac, H4K8ac and H4K12ac) facilitates chromatin loading of MCM complexes, promoting DNA replication licensing. Acts as a positive regulator of centromeric CENPA assembly: recruited to centromeres and mediates histone acetylation, thereby preventing centromere inactivation mediated by SUV39H1, possibly by increasing histone turnover/exchange. Involved in nucleotide excision repair: phosphorylation by ATR in response to ultraviolet irradiation promotes its localization to DNA damage sites, where it mediates histone acetylation to facilitate recruitment of XPC at the damaged DNA sites. Acts as an inhibitor of NF-kappa-B independently of its histone acetyltransferase activity. Plays a central role in the maintenance of leukemia stem cells in acute myeloid leukemia (AML). Acts by mediating acetylation of histone H3 at ‘Lys-14’ (H3K14ac), thereby facilitating the processivity of RNA polymerase II to maintain the high expression of key genes, such as HOXA9 and HOXA10 that help to sustain the functional properties of leukemia stem cells.

Subunit / interactions. Component of the HBO1 complex composed of KAT7/HBO1, MEAF6, ING4 or ING5, and one scaffold subunit: complexes containing BRPF scaffold (BRPF1, BRD1/BRPF2 or BRPF3) direct KAT7/HBO1 specificity towards H3K14ac, while complexes containing JADE scaffold (JADE1, JADE2 and JADE3) mediate acetylation of histone H4. Interacts with MCM2 and ORC1. Interacts with the androgen receptor (AR); in the presence of dihydrotestosterone. Interacts with CDT1. Interacts with MAP2K1 and CUL1. Interacts with p53/TP53; leading to inhibit histone acetyltransferase activity. Interacts with MIS18BP1.

Subcellular location. Nucleus. Chromosome. Centromere. Cytoplasm. Cytosol.

Tissue specificity. Ubiquitously expressed, with highest levels in testis.

Post-translational modifications. Phosphorylated at Ser-50 and Ser-53 by ATR in response to DNA damage, promoting its ubiquitination by the CRL4(DDB2) complex and subsequent degradation. Phosphorylation at Ser-50 and Ser-53 by ATR in response to ultraviolet-induced DNA, promotes localization to DNA damage sites. Phosphorylation at Ser-57 by PLK1 during mitosis seems important for prereplicative complex formation and DNA replication licensing, and requires prior phosphorylation at Thr-85 and Thr-88 by CDK1. Phosphorylated by MAP2K1, which accelerates its degradation. Ubiquitinated at Lys-338, leading to proteasomal degradation. Ubiquitinated by the CRL4(DDB2) complex following phosphorylation by ATR, leading to its subsequent degradation. Autoacetylation at Lys-432 is required for proper function.

Activity regulation. Histone acetyltransferase activity is inhibited by GMNN in the context of a complex with CDT1, inhibiting histone H4 acetylation and DNA replication licensing. Selectively inhibited by WM-3835 (N’-(4-fluoro-5-methyl-[1,1’-biphenyl]-3-carbonyl)-3- hydroxybenzenesulfonohydrazide) inhibitor.

Domain organisation. The C2HC MYST-type zinc finger is required for interaction with MCM2 and ORC1. The N-terminus is involved in transcriptional repression, while the C-terminus mediates AR-interaction.

Similarity. Belongs to the MYST (SAS/MOZ) family.

Isoforms (5)

UniProt ID	Names	Canonical?
O95251-1	1	yes
O95251-2	2
O95251-3	3
O95251-4	4
O95251-5	5

RefSeq proteins (6): NP_001186084, NP_001186085, NP_001186086, NP_001186087, NP_001333635, NP_008998* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002515	Znf_C2H2C	Repeat
IPR002717	HAT_MYST-type	Domain
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily
IPR036060	Znf_C2H2C_sf	Homologous_superfamily
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR040706	Zf-MYST	Domain
IPR050603	MYST_HAT	Family

Pfam: PF01530, PF01853, PF17772

Enzyme classification (BRENDA):

• EC 2.3.1.48 — histone acetyltransferase (BRENDA: 41 organisms, 681 substrates, 1134 inhibitors, 140 Km, 96 kcat entries)

Substrate kinetics (BRENDA)

27 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ACETYL-COA	0.0002–0.046	51
HISTONE H3	0.007–2.09	23
HISTONE H4	—	11
HISTONE H4 PEPTIDE	0.0208–0.197	7
HISTONE	0.075–1.4	6
HISTONE H3 TAIL PEPTIDE	0.044–0.112	4
PICCOLONUA4 PEPTIDE	0.135–0.372	4
3-AZIDOPROPIONYL-COA	0.0002–0.0086	3
4-PENTYNOYL-COA	0.0009–0.0859	3
SPERMIDINE	0.18–0.27	3
5-HEXYNOYL-COA	0.0006–0.0117	2
6-HEPTYNOYL-COA	0.0003–0.0237	2
HISTONE H3-PEPTIDE	0.05–0.49	2
PROTEIN P53	1.28–4.63	2
3-AZIDOPROPANOYL-COA	0.0103	1

Catalyzed reactions (Rhea), 1 shown:

• L-lysyl-[histone] + acetyl-CoA = N(6)-acetyl-L-lysyl-[histone] + CoA + H(+) (RHEA:21992)

UniProt features (78 total): modified residue 20, strand 13, helix 10, binding site 8, mutagenesis site 6, compositionally biased region 5, splice variant 3, turn 3, zinc finger region 2, cross-link 2, sequence conflict 2, chain 1, domain 1, active site 1, region of interest 1

Structure

Experimental structures (PDB)

8 structures.

PDB	Method	Resolution (Å)
7D0P	X-RAY DIFFRACTION	1.8
7D0R	X-RAY DIFFRACTION	1.95
6MAK	X-RAY DIFFRACTION	2.13
6MAJ	X-RAY DIFFRACTION	2.14
7D0Q	X-RAY DIFFRACTION	2.21
7D0S	X-RAY DIFFRACTION	2.3
5GK9	X-RAY DIFFRACTION	2.4
7D0O	X-RAY DIFFRACTION	2.51

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95251-F1	73.21	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 508 (proton donor/acceptor)

Ligand- & substrate-binding residues (8): 368; 371; 384; 388; 475–477; 483–488; 512; 521

Post-translational modifications (22): 10, 50, 53, 57, 64, 85, 88, 102, 104, 111, 124, 128, 158, 162, 164, 178, 199, 277, 432, 506 …

Mutagenesis-validated functional residues (6):

Position	Phenotype
50–53	impaired phosphorylation by atr, leading to decreased ubiquitination and increased stability in response to dna damage.
57	leads to cell cycle arrest in the g1/s phase.
338	decreases ubiquitination.
371	no interaction with mcm2 and orc1.
485	abolishes histone acetyltransferase activity.
508	abolished histone acetyltransferase activity.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-3214847	HATs acetylate histones
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization

MSigDB gene sets: 364 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, RNGTGGGC_UNKNOWN, CREL_01, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_POSITIVE_REGULATION_OF_DNA_REPLICATION, GOBP_NATURAL_KILLER_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_ERYTHROCYTE_DIFFERENTIATION, GOBP_MYELOID_CELL_HOMEOSTASIS, TGCGCANK_UNKNOWN, GOBP_REGULATION_OF_DNA_TEMPLATED_DNA_REPLICATION, GOBP_ERYTHROCYTE_HOMEOSTASIS, GCM_ZNF198, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_GROWTH, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION

GO Biological Process (33): regulation of cell growth (GO:0001558), natural killer cell differentiation (GO:0001779), DNA replication (GO:0006260), regulation of DNA replication (GO:0006275), DNA repair (GO:0006281), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), internal peptidyl-lysine acetylation (GO:0018393), regulation of DNA-templated DNA replication initiation (GO:0030174), T cell differentiation (GO:0030217), stress-activated protein kinase signaling cascade (GO:0031098), positive regulation of DNA-templated transcription, elongation (GO:0032786), positive regulation of erythrocyte differentiation (GO:0045648), positive regulation of DNA replication (GO:0045740), transcription initiation-coupled chromatin remodeling (GO:0045815), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of cell cycle (GO:0051726), response to sorbitol (GO:0072708), response to hydroxyurea (GO:0072710), response to actinomycin D (GO:0072716), response to dithiothreitol (GO:0072720), response to anisomycin (GO:0072739), DNA replication-dependent chromatin disassembly (GO:0140889), positive regulation of protein localization to nucleus (GO:1900182), positive regulation of hematopoietic stem cell proliferation (GO:1902035), regulation of DNA biosynthetic process (GO:2000278), regulation of nucleotide-excision repair (GO:2000819), chromatin organization (GO:0006325), chromatin remodeling (GO:0006338), DNA damage response (GO:0006974), positive regulation of macromolecule biosynthetic process (GO:0010557), epigenetic regulation of gene expression (GO:0040029), obsolete positive regulation of nucleobase-containing compound metabolic process (GO:0045935)

GO Molecular Function (18): chromatin binding (GO:0003682), DNA replication origin binding (GO:0003688), transcription coregulator activity (GO:0003712), histone acetyltransferase activity (GO:0004402), zinc ion binding (GO:0008270), histone H3 acetyltransferase activity (GO:0010484), histone H4 acetyltransferase activity (GO:0010485), histone H3K14 acetyltransferase activity (GO:0036408), histone H3K23 acetyltransferase activity (GO:0043994), histone H4K5 acetyltransferase activity (GO:0043995), histone H4K8 acetyltransferase activity (GO:0043996), histone H4K12 acetyltransferase activity (GO:0043997), histone H3K4 acetyltransferase activity (GO:0044016), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746), metal ion binding (GO:0046872), protein-lysine-acetyltransferase activity (GO:0061733)

GO Cellular Component (11): histone acetyltransferase complex (GO:0000123), chromosome, centromeric region (GO:0000775), chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), chromosome (GO:0005694), cytosol (GO:0005829), histone H3-K14 acetyltransferase complex (GO:0036409), site of DNA damage (GO:0090734), cytoplasm (GO:0005737), H3 histone acetyltransferase complex (GO:0070775)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Chromatin modifying enzymes	1
Chromatin organization	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
histone H3 acetyltransferase activity	3
histone H4 acetyltransferase activity	3
lymphocyte differentiation	2
DNA metabolic process	2
DNA replication	2
transcription by RNA polymerase II	2
positive regulation of DNA-templated transcription	2
response to nitrogen compound	2
binding	2
histone acetyltransferase activity	2
chromosome	2
cell growth	1
regulation of growth	1
regulation of cellular component organization	1
natural killer cell activation	1
DNA biosynthetic process	1
regulation of DNA metabolic process	1
DNA damage response	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
regulation of DNA-templated transcription	1
internal protein amino acid acetylation	1
peptidyl-lysine acetylation	1
DNA replication initiation	1
regulation of DNA-templated DNA replication	1
T cell activation	1
cellular response to stress	1
intracellular signal transduction	1
DNA-templated transcription elongation	1
regulation of DNA-templated transcription elongation	1
erythrocyte differentiation	1
positive regulation of myeloid cell differentiation	1
regulation of erythrocyte differentiation	1
regulation of DNA replication	1
positive regulation of DNA metabolic process	1
transcription initiation at RNA polymerase II promoter	1
positive regulation of gene expression, epigenetic	1
regulation of transcription by RNA polymerase II	1

Protein interactions and networks

STRING

1952 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KAT7	ING4	Q9UNL4	998
KAT7	ING5	Q8WYH8	987
KAT7	JADE1	Q6IE81	982
KAT7	MEAF6	Q9HAF1	955
KAT7	CDT1	Q9H211	941
KAT7	BRPF1	P55201	931
KAT7	BRPF3	Q9ULD4	916
KAT7	ORC1	Q13415	886
KAT7	BRD1	O95696	881
KAT7	EP300	Q09472	803
KAT7	H4C7	Q99525	783
KAT7	H4C16	P02304	768
KAT7	SIX1	Q15475	729
KAT7	ING1	Q9UK53	697
KAT7	JADE2	Q9NQC1	696

IntAct

148 interactions, top by confidence:

A	B	Type	Score
VIM	KAT7	psi-mi:“MI:0915”(physical association)	0.750
KAT7	VIM	psi-mi:“MI:0915”(physical association)	0.750
CDK11B	KAT7	psi-mi:“MI:0915”(physical association)	0.730
CDK11B	KAT7	psi-mi:“MI:0403”(colocalization)	0.730
KAT7	CDK11B	psi-mi:“MI:0407”(direct interaction)	0.730
KAT7	CDK11B	psi-mi:“MI:0915”(physical association)	0.730
JADE1	KAT7	psi-mi:“MI:0915”(physical association)	0.720
JADE1	KAT7	psi-mi:“MI:0914”(association)	0.720
KAT7	JADE1	psi-mi:“MI:0914”(association)	0.720
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
PLK1	KAT7	psi-mi:“MI:0407”(direct interaction)	0.670
PLK1	KAT7	psi-mi:“MI:0915”(physical association)	0.670
KAT7	AR	psi-mi:“MI:0915”(physical association)	0.590
AR	KAT7	psi-mi:“MI:0407”(direct interaction)	0.590
MCRS1	KAT7	psi-mi:“MI:0915”(physical association)	0.560
KAT7	MCRS1	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (270): KAT7 (Affinity Capture-MS), KAT7 (Affinity Capture-MS), KAT7 (Affinity Capture-MS), KAT7 (Two-hybrid), CEP70 (Two-hybrid), KAT7 (Affinity Capture-MS), KAT7 (Two-hybrid), HOOK2 (Two-hybrid), KAT7 (Two-hybrid), KAT7 (Two-hybrid), NINL (Two-hybrid), KCTD13 (Two-hybrid), JADE1 (Co-localization), JADE1 (Affinity Capture-Western), KAT7 (Affinity Capture-Western)

ESM2 similar proteins: A0A0L0P4F8, A3KN83, A8XEA2, A9Q1D5, A9UL78, B2GUV7, G5EDG2, O17966, O36966, O95251, P04786, P07799, P0CL88, P0CL89, P11387, P30181, P30189, P41511, P41512, P93119, Q00313, Q04750, Q05D44, Q06698, Q07050, Q09475, Q23243, Q23541, Q27746, Q4IEV4, Q4P3S3, Q54RC3, Q54UU6, Q5BJL5, Q5F1R6, Q5F371, Q5SVQ0, Q5UQH6, Q61T02, Q689Z5

Diamond homologs: A2A5N8, B1B1A0, D3YUG0, D3YXK1, D3ZWK4, E1C2V1, O02274, O60284, O95251, P39769, P59178, P70047, P70475, P78364, P97500, Q01538, Q05BQ5, Q1JQD9, Q1RNF8, Q29L50, Q32N90, Q3MIF2, Q4V7W5, Q5DTW2, Q5R737, Q5SVQ0, Q5VUG0, Q5VXD3, Q64028, Q6DIN3, Q6P5G3, Q6SPE9, Q6SPF0, Q7Z3H4, Q80TY4, Q810T5, Q8BLB7, Q8C8Y5, Q8CFC2, Q8CHP6

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
CDK1	up-regulates	KAT7	phosphorylation
PLK1	up-regulates	KAT7	phosphorylation
PRKD1	“up-regulates quantity by stabilization”	KAT7	phosphorylation
HUWE1	“down-regulates quantity by destabilization”	KAT7	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 126 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane	5	21.3×	4e-04
Maturation of DENV proteins	6	16.1×	3e-04
Influenza Infection	5	11.1×	5e-03
HATs acetylate histones	11	11.0×	2e-06
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	5	9.3×	9e-03
Chromatin organization	7	7.2×	4e-03
Chromatin modifying enzymes	7	6.4×	6e-03
Major pathway of rRNA processing in the nucleolus and cytosol	8	6.2×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of DNA replication	8	26.6×	4e-07
regulation of cell growth	6	12.1×	1e-03
regulation of cell cycle	12	8.1×	7e-06
chromatin remodeling	9	6.0×	2e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — BLCA.

Clinical variants and AI predictions

ClinVar

66 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	50
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2193 predictions. Top by Δscore:

Variant	Effect	Δscore
17:49788845:GGAAG:G	donor_gain	1.0000
17:49788846:GAAGG:G	donor_gain	1.0000
17:49788847:A:T	donor_gain	1.0000
17:49788847:AAGGT:A	donor_loss	1.0000
17:49788848:AGG:A	donor_loss	1.0000
17:49788849:GGTG:G	donor_loss	1.0000
17:49788850:GTGA:G	donor_loss	1.0000
17:49792014:GC:G	donor_gain	1.0000
17:49792029:TCAAG:T	donor_loss	1.0000
17:49792030:CAAG:C	donor_loss	1.0000
17:49792031:AAG:A	donor_loss	1.0000
17:49792033:GGTAA:G	donor_loss	1.0000
17:49792034:G:C	donor_loss	1.0000
17:49792035:T:A	donor_loss	1.0000
17:49796736:A:AG	acceptor_gain	1.0000
17:49796737:A:AG	acceptor_gain	1.0000
17:49796737:AAATT:A	acceptor_gain	1.0000
17:49796738:A:G	acceptor_gain	1.0000
17:49796738:AATT:A	acceptor_gain	1.0000
17:49796738:AATTG:A	acceptor_gain	1.0000
17:49796739:A:G	acceptor_gain	1.0000
17:49796739:ATT:A	acceptor_gain	1.0000
17:49796739:ATTG:A	acceptor_gain	1.0000
17:49796741:T:A	acceptor_gain	1.0000
17:49796742:G:A	acceptor_gain	1.0000
17:49796927:G:A	donor_loss	1.0000
17:49796928:T:G	donor_loss	1.0000
17:49798311:T:TA	acceptor_gain	1.0000
17:49798314:TTTAG:T	acceptor_loss	1.0000
17:49798317:A:AG	acceptor_gain	1.0000

AlphaMissense

4028 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:49798531:T:A	C185S	1.000
17:49798531:T:C	C185R	1.000
17:49798531:T:G	C185G	1.000
17:49798532:G:A	C185Y	1.000
17:49798532:G:C	C185S	1.000
17:49798532:G:T	C185F	1.000
17:49798533:T:G	C185W	1.000
17:49798546:T:A	C190S	1.000
17:49798546:T:C	C190R	1.000
17:49798546:T:G	C190G	1.000
17:49798547:G:A	C190Y	1.000
17:49798547:G:C	C190S	1.000
17:49798547:G:T	C190F	1.000
17:49798548:T:G	C190W	1.000
17:49798552:T:C	S192P	1.000
17:49798553:C:T	S192F	1.000
17:49798558:G:A	G194R	1.000
17:49798558:G:C	G194R	1.000
17:49805363:G:A	G194E	1.000
17:49805363:G:T	G194V	1.000
17:49805366:A:G	H195R	1.000
17:49805367:C:A	H195Q	1.000
17:49805367:C:G	H195Q	1.000
17:49805369:T:C	L196P	1.000
17:49805374:G:A	G198R	1.000
17:49805374:G:C	G198R	1.000
17:49805375:G:A	G198E	1.000
17:49805375:G:T	G198V	1.000
17:49805389:C:A	H203N	1.000
17:49805389:C:G	H203D	1.000

dbSNP variants (sampled 300 via entrez): RS1000080818 (17:49811498 G>A), RS1000179058 (17:49824216 C>T), RS1000186183 (17:49807139 G>T), RS1000240913 (17:49811380 T>A), RS1000259632 (17:49817332 A>G), RS1000289235 (17:49804359 A>G), RS1000331392 (17:49832556 G>A,C), RS1000469040 (17:49823858 T>G), RS1000656065 (17:49815681 A>G), RS1000690845 (17:49803655 A>C), RS1000695176 (17:49817024 C>T), RS1000710679 (17:49822602 G>A,C), RS1000733008 (17:49787670 G>A), RS1000740196 (17:49822373 G>A,T), RS1000808603 (17:49832347 T>C)

Disease associations

OMIM: gene MIM:609880 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004602_296	Mean corpuscular volume	1.000000e-23
GCST004630_218	Mean corpuscular hemoglobin	5.000000e-15
GCST005993_16	Mean corpuscular hemoglobin	3.000000e-10
GCST006011_54	Mean corpuscular volume	7.000000e-11
GCST90002396_666	Mean reticulocyte volume	8.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0010701	mean reticulocyte volume

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3774299 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — 2.3.1.48 Histone acetyltransferases (HATs)

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
PF-9363	Inhibition	7.15	pIC50

ChEMBL bioactivities

132 potent at pChembl≥5 of 185 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.10	Ki	8	nM	CHEMBL5928174
7.97	Ki	10.6	nM	CHEMBL5940985
7.72	Ki	19.2	nM	CHEMBL5885987
7.70	Ki	20	nM	CHEMBL5812221
7.70	Ki	20	nM	CHEMBL5853409
7.52	IC50	30	nM	CHEMBL5723365
7.52	Ki	30	nM	CHEMBL5993180
7.52	Ki	30	nM	CHEMBL5830107
7.52	Ki	30	nM	CHEMBL5955544
7.47	Kd	34	nM	CHEMBL5723365
7.40	Ki	40	nM	CHEMBL5785798
7.40	Ki	40	nM	CHEMBL5883288
7.40	Ki	40	nM	CHEMBL5941367
7.40	Ki	40	nM	CHEMBL5723326
7.31	Ki	49	nM	CHEMBL5853561
7.30	Ki	50	nM	CHEMBL5852195
7.30	Ki	50	nM	CHEMBL5723326
7.30	Ki	50	nM	CHEMBL5959733
7.30	Ki	50	nM	CHEMBL6005841
7.30	Ki	50	nM	CHEMBL5996948
7.25	Ki	56	nM	CHEMBL5792567
7.22	Ki	60	nM	CHEMBL5980695
7.22	Ki	60	nM	CHEMBL5998930
7.22	Ki	60	nM	CHEMBL5947618
7.22	Ki	60	nM	CHEMBL5723326
7.10	Ki	80	nM	CHEMBL5857566
7.05	Ki	90	nM	CHEMBL5818085
7.05	Ki	90	nM	CHEMBL5963038
7.05	Ki	90	nM	CHEMBL5925551
7.02	Ki	95	nM	CHEMBL5798744
7.00	Ki	100	nM	CHEMBL5771110
6.92	Ki	120	nM	CHEMBL5871508
6.92	Ki	120	nM	CHEMBL6057979
6.92	Ki	120	nM	CHEMBL5886450
6.92	Ki	120	nM	CHEMBL5924783
6.92	Ki	120	nM	CHEMBL5867166
6.91	Ki	124	nM	CHEMBL5810460
6.86	Ki	137	nM	CHEMBL5873968
6.85	Ki	140	nM	CHEMBL5792825
6.85	Ki	140	nM	CHEMBL5938038
6.82	Ki	150	nM	CHEMBL5993009
6.82	Ki	150	nM	CHEMBL6000330
6.80	Ki	160	nM	CHEMBL5815468
6.72	Ki	190	nM	CHEMBL5756543
6.70	Ki	200	nM	CHEMBL5873394
6.66	Ki	220	nM	CHEMBL6000207
6.66	Ki	220	nM	CHEMBL5808891
6.66	Ki	220	nM	CHEMBL5779221
6.66	Ki	220	nM	CHEMBL5908760
6.64	Ki	230	nM	CHEMBL5842425

PubChem BioAssay actives

4 with measured affinity, of 19 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-fluoro-N’-naphthalen-2-ylsulfonylbenzohydrazide	2138647: Inhibition of recombinant human KAT7 catalytic domain using H3 peptide and [3H]-acetyl-coA as substrate incubated for 1 hr by liquid scintillation counter analysis	ic50	0.6100	uM
N-[2-(2-fluorophenyl)-2-oxoethyl]quinoline-8-sulfonamide	2138647: Inhibition of recombinant human KAT7 catalytic domain using H3 peptide and [3H]-acetyl-coA as substrate incubated for 1 hr by liquid scintillation counter analysis	ic50	0.7600	uM
4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxopyrazol-1-yl]benzoic acid	1891244: Inhibition of MYST2 (unknown origin) using biotinylated H4 (1 to 25)-GSGSK peptide as substrate incubated for 1 hr by AlphaLISA assay	ic50	7.8100	uM

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
trichostatin A	decreases expression, affects expression, affects cotreatment	3
sodium arsenite	decreases expression, increases expression	2
entinostat	decreases expression, affects cotreatment	2
Panobinostat	decreases expression, affects cotreatment	2
Vehicle Emissions	decreases reaction, increases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Particulate Matter	decreases reaction, increases expression, increases abundance	2
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
arsenite	decreases reaction, affects binding	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cypermethrin	increases expression	1
coumarin	affects phosphorylation	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Air Pollutants	decreases expression, increases abundance, affects cotreatment	1
Aspirin	decreases expression	1
Caffeine	affects phosphorylation	1
Doxorubicin	decreases expression	1
Dust	increases expression	1

ChEMBL screening assays

21 unique, capped per target: 20 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3779403	Binding	Inhibition of HBO1 (unknown origin) using N-terminal histone H3 substrate at 100 uM by fluorescence assay in presence of [3H]acetyl-CoA relative to control	KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases. — J Med Chem
CHEMBL5723070	Functional	Affinity Biochemical interaction: (AlphaScreen) EUB0001094a MYST2	Affinity Biochemical Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

8 cell lines: 8 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7XT	Abcam Raji KAT7 KO	Cancer cell line	Male
CVCL_B9YI	Abcam THP-1 KAT7 KO	Cancer cell line	Male
CVCL_C7AA	Abcam PC-3 KAT7 KO	Cancer cell line	Male
CVCL_E0UE	Ubigene Hep G2 KAT7 KO	Cancer cell line	Male
CVCL_ST93	HAP1 KAT7 (-) 1	Cancer cell line	Male
CVCL_ST94	HAP1 KAT7 (-) 2	Cancer cell line	Male
CVCL_XP92	HAP1 KAT7 (-) 3	Cancer cell line	Male
CVCL_XP93	HAP1 KAT7 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer